CTH

Across TCGA pan-cancer cohorts, CTH mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CTH data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTH mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CTH expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where CTH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.474	0.245	.011	31	view →
GBM	OS	Median	All	0.711	0.358	<.001	22	view →
CCRCC	OS	Quartile	III,IV	0.882	0.479	.028	5	view →
LUAD	DFS	Median	III,IV	0.671	0.328	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CTH–PDAC (DFS)

Open the PDAC breakdown →